Ignite Creation Date:
2024-05-06 @ 7:14 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02490176
Status:
UNKNOWN
Last Update Posted:
2016-02-29
First Post:
2015-07-02
Brief Title:
Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters
Sponsor:
Chinese PLA General Hospital
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure
Status:
UNKNOWN
Status Verified Date:
2016-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Glucagon-like peptide-1 GLP-1 is an incretin hormone that regulates plasma glucose and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction The investigators planned to evaluate the effects of liraglutide on haemodynamic parameters in patients with heart failure
Detailed Description:
Heart failure HF is a major cause of morbidity and mortality world wide Glucagon-like peptide-1 GLP-1 is an incretin hormone that regulates plasma glucose and has direct effects on the cardiovascular system In our previous study the GLP-1 analogue liraglutide could improve left ventricular function in patients with non-ST-segment elevation myocardial infarction However the effects of GLP-1 on HF patients remain unclear Pulse indicator continuous cardiac output PiCCO technology is a combination of transpulmonary thermodilution and pulse contour analysis which measures hemodynamic variables left ventricular ejection fraction volumes and mass in a fast and feasible way Therefore the aim of this study was to evaluate the effects of liraglutide on hemodynamic variables in HF patients using the PiCCO system
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None